13/07/2020
Logo of Marie Skłodowska-Curie Actions

Design and production of a SARS-CoV-2 nanotech vaccine.

Dieses Angebot der Gasteinrichtung ist nicht mehr aktuell


  • ANGEBOTSFRIST
    04/09/2020 18:30 - Europe/Brussels
  • EU-FORSCHUNGSRAHMENPROGRAMM
    H2020 / Marie Skłodowska-Curie Actions
  • STANDORT
    Mexico, Monterrey
  • ORGANISATION/EINRICHTUNG
    Tecnologico de Monterrey
  • ABTEILUNG
    Centro de Biotecnología-FEMSA
  • LABORATORY
    ALVAREZ-TRUJILLO LAB

COVID-19 has crudely demonstrated that our technologies used to produce vaccines are obsolete. The Alvarez-Trujillo Lab has previous experience in the development of recombinant vaccines against influenza. In response to the current pandemic caused by SARS-CoV-2, we are integrating our experience in recombinant vaccine development with micro and nanotechnology resources to develop an extended-release and cost-effective vaccine against COVID-19. Our design strategy is based on a combination of recombinant technology and nanotechnology. We aim to demonstrate the efficacy and safety of an anti-SARS-CoV-2 vaccine based on the covalent linkage of nanoparticles and a recombinant antigen inspired by the structure of the receptor binding domain of the Spike protein of SARS-CoV-2.

Disclaimer:

The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.